Stay updated on Nivolumab in AML Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in AML Prevention Clinical Trial page.

Latest updates to the Nivolumab in AML Prevention Clinical Trial page
- Check2 days agoChange DetectedThe page’s footer revision identifier was updated from v3.5.2 to v3.5.3, reflecting a site/version maintenance update.SummaryDifference0.0%

- Check9 days agoChange DetectedA new update entry was added on 2026-04-13 with Revision: v3.5.2; the prior entries from 2026-04-08 and 2025-10, along with Revision: v3.5.0, were removed.SummaryDifference0.2%

- Check16 days agoChange DetectedLast update entries were added for 2026-04-09 and 2026-04-08, and earlier dates 2026-04-01 and 2026-04-02 were removed. These are administrative timestamp updates and do not change trial content or eligibility criteria.SummaryDifference0.1%

- Check24 days agoChange DetectedTwo new dates, 2026-04-01 and 2026-04-02, were added to the Study Record Dates, reflecting recent page edits.SummaryDifference0.1%

- Check31 days agoChange DetectedAdditions were made on 2026-03-24 and 2026-03-25. Deletions occurred on 2026-03-17 and 2026-03-18, affecting non-core sections of the page such as metadata and publications.SummaryDifference0.1%

- Check38 days agoChange DetectedSite release notes show an upgrade to version 3.5.0 with entries dated 2026-03-17 and 2026-03-18, replacing the previous version 3.4.3 dated 2026-03-10 and 2026-03-11.SummaryDifference0.1%

Stay in the know with updates to Nivolumab in AML Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in AML Prevention Clinical Trial page.